Effects of D-amino acid oxidase inhibition on memory performance and long-term potentiation in vivo

Pharmacology Research and Perspectives

Volumn 1, Issue 1, 2013, Pages

  Hopkins, Seth C ^a   Campbell, Una C ^a   Heffernan, Michele L R ^a   Spear, Kerry L ^a   Jeggo, Ross D ^b   Spanswick, David C ^b,c,d   Varney, Mark A ^a   Large, Thomas H ^a  

^a SUNOVION PHARMACEUTICALS INC   (United States)

^b NEUROSOLUTIONS LTD   (United Kingdom)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Cognition; d amino acid oxidase; d cycloserine; d Serine; Long term potentiation; NMDA Receptors

Indexed keywords

EID: 84940268053     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.7     Document Type: Article

References (29)

1. Chen C, Kim JJ, Thompson RF, Tonegawa S (1996). Hippocampal lesions impair contextual fear conditioning in two strains of mice. Behav Neurosci 110: 1177–1180.
2. Depoortere R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, et al. (2005). Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30: 1963–1985.
3. Dorsey JM, Heffernan MLR, Fang QK, Foglesong RJ, Hopkins SC, Ogbu CO, et al. (inventors), Sepracor Inc. (assignee) (2008). Fused heterocycles. US20080004328. 03 January.
4. Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, et al. (2004). Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res 71: 239–248.
5. Duplantier AJ, Becker SL, Bohanon MJ, Borzilleri KA, Chrunyk BA, Downs JT, et al. (2009). Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors. J Med Chem 52: 3576–3585.
6. Ferraris DV, Tsukamoto T (2011). Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia. Curr Pharm Des 17: 103–111.
7. Fujihira T, Kanematsu S, Umino A, Yamamoto N, Nishikawa T (2007). Selective increase in the extracellular D-serine contents by D-cycloserine in the rat medial frontal cortex. Neurochem Int 51: 233–236.
8. Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, et al. (2005). A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology 179: 144–150.
9. Hammond RS, Tull LE, Stackman RW (2004). On the delay-dependent involvement of the hippocampus in object recognition memory. Neurobiol Learn Mem 82: 26–34.
10. Heffernan MLR, Dorsey J, Fang Q, Foglesong R, Hopkins S, Ogbu C, et al. (inventors), Sepracor Inc. (assignee) (2009). Fused heterocycles. US 7,579,370 B2. 25 August.
11. Hopkins CR (2011). ACS Chemical Neuroscience Molecule Spotlight on RG1678. ACS Chem Neurosci 2: 685–686.
12. Horiike K, Tojo H, Arai R, Nozaki M, Maeda T (1994). D-amino-acid oxidase is confined to the lower brain stem and cerebellum in rat brain: regional differentiation of astrocytes. Brain Res 652: 297–303.
13. Horio M, Mori H, Hashimoto K (2013). Is D-Cycloserine a Prodrug for D-Serine in the Brain? Biol Psychiatry 73: e33–e34.
14. Litz BT, Salters-Pedneault K, Steenkamp MM, Hermos JA, Bryant RA, Otto MW, et al. (2012). A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res 46: 1184–1190.
15. Maren S, De OB, Fanselow MS (1994). Sex differences in hippocampal long-term potentiation (LTP) and Pavlovian fear conditioning in rats: positive correlation between LTP and contextual learning. Brain Res 661: 25–34.
16. Morikawa A, Hamase K, Inoue T, Konno R, Niwa A, Zaitsu K (2001). Determination of free D-aspartic acid, D-serine and D-alanine in the brain of mutant mice lacking D-amino acid oxidase activity. J Chromatogr B Biomed Sci Appl 757: 119–125.
17. Nagata Y, Horiike K, Maeda T (1994). Distribution of free D-serine in vertebrate brains. Brain Res 634: 291–295.
18. National Institutes of Health (1996). Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
19. Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, et al. (2010). Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 67: 365–370.
20. Papouin T, Ladepeche L, Ruel J, Sacchi S, Labasque M, Hanini M, et al. (2012). Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 150: 633–646.
21. Paxinos G, Watson C (1998). The rat brain in stereotaxic coordinates. Academic Press, New York.
22. Rais R, Thomas AG, Wozniak K, Wu Y, Jaaro-Peled H, Sawa A, et al. (2012). Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice. Drug Metab Dispos 40: 2067–2073.
23. Schell MJ (2004). The N-methyl D-aspartate receptor glycine site and D-serine metabolism: an evolutionary perspective. Philos Trans R Soc Lond B Biol Sci 359: 943–964.
24. Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch SI (1996). d-Cycloserine enhances implicit memory in Alzheimer patients. Neurology 46: 420–424.
25. Smith SM, Uslaner JM, Yao L, Mullins CM, Surles NO, Huszar SL, et al. (2009). The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine. J Pharmacol Exp Ther 328: 921–930.
26. Sparey T, Abeywickrema P, Almond S, Brandon N, Byrne N, Campbell A, et al. (2008). The discovery of fused pyrrole carboxylic acids as novel, potent D-amino acid oxidase (DAO) inhibitors. Bioorg Med Chem Lett 18: 3386–3391.
27. Strick CA, Li C, Scott L, Harvey B, Hajos M, Steyn SJ, et al. (2011). Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain. Neuropharmacology 61: 1001–1015.
28. Tsai GE, Falk WE, Gunther J, Coyle JT (1999). Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry 156: 467–469.
29. Yang CR, Svensson KA (2008). Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther 120: 317–332.